KR20150093172A - 설사의 치료 및/또는 예방을 위한 생균제 균주들 - Google Patents
설사의 치료 및/또는 예방을 위한 생균제 균주들 Download PDFInfo
- Publication number
- KR20150093172A KR20150093172A KR1020157015784A KR20157015784A KR20150093172A KR 20150093172 A KR20150093172 A KR 20150093172A KR 1020157015784 A KR1020157015784 A KR 1020157015784A KR 20157015784 A KR20157015784 A KR 20157015784A KR 20150093172 A KR20150093172 A KR 20150093172A
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- diarrhea
- expression
- treatment
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
- C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
도 2는 NHE3 단백질의 결장 발현에 대한 균주 Bacillus subtilis CU1로의 치료 효과를 보여주는 것이다. 형광 강도/㎛2는 대조군(흰색), 그리고 CU1으로 치료한 후(검정색)에 대한 것이다. *p<0.005
도 3는 CFTR 단백질의 결장 발현에 대한 균주 Lactobacillus plantarum로의 치료 효과의 부재를 보여주는 것이다. 형광 강도/㎛2는 대조군(흰색), 그리고 LR 로 치료한 후(검정색)에 대한 것이다. *p<0.005
도 4는 NHE3 단백질의 결장 발현에 대한 균주 Lactobacillus plantarum로의 치료 효과의 부재를 보여주는 것이다. 형광 강도/㎛2는 대조군(흰색), 그리고 LR 로 치료한 후(검정색)에 대한 것이다. *p<0.005
도 5는 생쥐에게 LPS(15 mg/kg) 또는 식염수를 정맥내 투여한 후 60분 동안(검정색)과 60 내지 120분 사이(흰색)에 대변으로 배출된 물(mg) (평균값± SEM, n=10-20)을 보여주는 것이다. T-: 식염수의 주사를 맞은 CU1으로 처리되지 않은 생쥐들, T+: LPS의 주사를 맞은 CU1으로 처리되지 않은 생쥐들, T-/CU1: 식염수의 주사를 맞은 CU1으로 처리된 생쥐들, T+/CU1: LPS의 주사를 맞은 CU1으로 처리된 생쥐들. * P<0.05 대 T-; † P<0.05 대 T+
도 6는 생쥐에게 피마자유(castor oil)(200 L) 또는 식염수를 위내 투여한 후 60분 동안(검정색), 60 내지 120분 사이(회색), 및 120분 내지 180분 사이(흰색)에 대변으로 배출된 물(mg) (평균값± SEM, n=10-19)을 보여주는 것이다. T-: 식염수의 주사를 맞은 CU1으로 처리되지 않은 생쥐들, T+: 피마자유의 주사를 맞은 CU1으로 처리되지 않은 생쥐들, T-/CU1: 식염수의 주사를 맞은 CU1으로 처리된 생쥐들, T+/CU1: 피마자유의 주사를 맞은 CU1으로 처리된 생쥐들. * P<0.05 대 T-; † P<0.05 대 T+
Claims (10)
- 설사의 치료 및/또는 예방을 위한 생균제 균주(probiotic strain)를 선택하는 방법으로서,
- 결장 내 물의 분비에 관련된 적어도 하나의 수송체(transporter), 또는 결장 내 물의 흡수에 관련된 적어도 하나의 수송체의 발현에 대한 적어도 하나의 시험 균주의 효과를 측정하는 과정; 및
- 결장 내 물의 분비에 관련된 적어도 하나의 수송체의 발현의 감소, 및/또는 결장 내 물의 흡수에 관련된 적어도 하나의 수송체의 발현의 증가를 유도하는 적어도 하나의 균주를 선택하는 과정;
을 포함하는 것을 특징으로 하는 선택 방법. - 제 1 항에 있어서, 상기 방법은,
- CFTR 단백질 및/또는 NHE3 단백질의 발현에 대한 적어도 하나의 시험 균주의 효과를 측정하는 과정; 및
- CFTR 단백질 발현의 감소 및/또는 NHE3 단백질 발현의 증가를 유도하는 적어도 하나의 균주를 선택하는 과정;
을 포함하는 것을 특징으로 하는 선택 방법. - 제 1 항 또는 제 2 항에 있어서, 상기 시험 균주는 효모 균주 또는 박테리아 균주인 것을 특징으로 하는 선택 방법.
- 제 3 항에 있어서, 상기 박테리아 균주는 Bacillus의 균주, 바람직하게는 Bacillus subtilis의 균주인 것을 특징으로 하는 선택 방법.
- 제 1 항 내지 제 4 항 중 어느 하나에 있어서, 상기 CFTR 단백질 및/또는 NHE3 단백질의 발현은, 전기 영동(electrophoresis), 웨스턴 블롯(Western blot), 면역 검정(immunoassay), 면역 조직 화학(immunohistochemistry), 면역 세포 화학(immunocytochemistry), 질량 분석(mass spectrometry), RT-PCR 또는 노던 블롯(Northern blot)에 의해 측정되는 것을 특징으로 하는 선택 방법.
- 설사의 치료 및/또는 예방에 사용하기 위한 것으로, 결장 내 물의 분비에 관련된 적어도 하나의 수송체의 발현의 감소 및/또는 결장 내 물의 흡수에 관련된 적어도 하나의 수송체의 발현의 증가를 유도하는 생균제 균주(a probiotic strain), 상기 생균제 균주의 배양에 의해 얻어지는 세포들(cells), 또는 상기 생균제 균주 또는 상기 세포들을 포함하는 조성물(composition).
- 제 6 항에 있어서, 상기 생균제 균주는 Bacillus subtilis의 균주인 것을 특징으로 하는 설사의 치료 및/또는 예방에 사용하기 위한, 생균제 균주, 세포들, 또는 조성물.
- 제 7 항에 있어서, 상기 생균제 균주는 2001년 10월 25일자로 CNCM에 번호 I-2745로 기탁되어 있는 Bacillus subtilis CU1의 균주인 것을 특징으로 하는 설사의 치료 및/또는 예방에 사용하기 위한, 생균제 균주, 세포들, 또는 조성물.
- 제 6 항 내지 제 8 항 중 어느 하나에 있어서, 상기 설사는 급성 설사 또는 만성 설사인 것을 특징으로 하는 설사의 치료 및/또는 예방에 사용하기 위한, 생균제 균주, 세포들, 또는 조성물.
- 제 6 항 내지 제 9 항 중 어느 하나에 있어서, 상기 설사는 감염성 근원 또는 비감염성 근원의 설사인 것을 특징으로 하는 설사의 치료 및/또는 예방에 사용하기 위한, 생균제 균주, 세포들, 또는 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1261916 | 2012-12-12 | ||
FR1261916A FR2999191B1 (fr) | 2012-12-12 | 2012-12-12 | Souches probiotiques pour le traitement et/ou la prevention de la diarrhee |
PCT/FR2013/053044 WO2014091160A1 (fr) | 2012-12-12 | 2013-12-12 | Souches probiotiques pour le traitement et/ou la prévention de la diarrhée |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150093172A true KR20150093172A (ko) | 2015-08-17 |
KR102181606B1 KR102181606B1 (ko) | 2020-11-23 |
Family
ID=48128446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020157015784A Active KR102181606B1 (ko) | 2012-12-12 | 2013-12-12 | 설사의 치료 및/또는 예방을 위한 생균제 균주들 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20160000840A1 (ko) |
EP (1) | EP2932265B1 (ko) |
JP (1) | JP6401180B2 (ko) |
KR (1) | KR102181606B1 (ko) |
CN (1) | CN105008924B9 (ko) |
CA (1) | CA2893990C (ko) |
DK (1) | DK2932265T3 (ko) |
ES (1) | ES2692660T3 (ko) |
FR (1) | FR2999191B1 (ko) |
PH (1) | PH12015501273B1 (ko) |
RU (1) | RU2642320C2 (ko) |
SG (1) | SG11201504542PA (ko) |
TW (1) | TWI602921B (ko) |
WO (1) | WO2014091160A1 (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3007655B1 (fr) * | 2013-06-28 | 2016-12-23 | Lesaffre & Cie | Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques |
BR112018074616A2 (pt) * | 2016-05-31 | 2019-04-02 | Evonik Degussa Gmbh | cepa de bacillus subtilis com atividade probiótica |
US11173184B2 (en) | 2016-05-31 | 2021-11-16 | Evonik Operations Gmbh | Bacillus subtilis strain with probiotic activity |
BE1027162B1 (nl) * | 2019-03-29 | 2020-11-05 | My Res Comm V | Bacillus coagulans en Bacillus subtilis voor de preventie en behandeling van functionele gastro-intestinale stoornissen |
CN113462597A (zh) * | 2021-06-29 | 2021-10-01 | 广西壮族自治区兽医研究所 | 一种产木质素过氧化物酶的枯草芽孢杆菌和含有该枯草芽孢杆菌的菌剂及其应用 |
CN114947134B (zh) * | 2022-05-06 | 2024-01-26 | 河北一然生物科技股份有限公司 | 嗜热链球菌s131在改善肠道健康及调节肠道菌群中的应用 |
CN116463258B (zh) * | 2023-04-12 | 2024-01-09 | 山东威曼宠物食品有限公司 | 一种用于预防宠物腹泻的凝结芽孢杆菌King27及菌剂、制备方法和应用 |
FR3153743A1 (fr) | 2023-10-05 | 2025-04-11 | Lesaffre Et Compagnie | Effet bénéfique d’une bactérie probiotique Bacillus subtilis sur l’inflammation de bas grade |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2837835B2 (ja) * | 1996-05-15 | 1998-12-16 | オリンパス光学工業株式会社 | 射出成形機における金型要素自動交換方法 |
KR20080073771A (ko) * | 2005-11-29 | 2008-08-11 | 케민 인더스트리즈, 인코포레이티드 | 위장관 및 면역-관련 질환의 예방 및 치료를 위한 바실루스pb6의 용도 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2528055B2 (ja) * | 1991-10-04 | 1996-08-28 | カルピス食品工業株式会社 | 鳥類飼料添加用腸内サルモネラ属細菌減少剤及びその使用法 |
FR2837835B1 (fr) * | 2002-03-29 | 2007-06-22 | Maria Urdaci | Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant |
AU2003277162C1 (en) | 2002-09-30 | 2009-12-24 | The Regents Of The University Of California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
RU2246537C2 (ru) * | 2002-11-11 | 2005-02-20 | Закрытое акционерное общество "КУЛ" | Штамм бактерий bacillus subtilis, используемый для получения пробиотического препарата, предназначенного для профилактики и лечения желудочно-кишечных заболеваний сельскохозяйственных животных, птицы и рыбы |
JP4805859B2 (ja) * | 2007-02-02 | 2011-11-02 | 全国農業協同組合連合会 | 飼料添加剤 |
JP2009044971A (ja) * | 2007-08-15 | 2009-03-05 | National Agriculture & Food Research Organization | 反芻家畜に対するプロバイオティック効果をサイレージ調製用乳酸菌に付加する新規酵母菌およびその利用 |
EP2279029A2 (en) * | 2008-03-25 | 2011-02-02 | The Regents of the University of California | Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator |
EP2341776A4 (en) * | 2008-09-19 | 2012-05-30 | Inst Oneworld Health | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES |
MX2011008131A (es) * | 2009-02-02 | 2012-01-20 | Chromocell Corp | Lineas celulares que expresan cftr y los métodos para utilizarlas. |
JP5769333B2 (ja) * | 2010-07-09 | 2015-08-26 | 雪印種苗株式会社 | セロトニン代謝性バチルス属菌 |
CN102732464A (zh) * | 2012-06-29 | 2012-10-17 | 扬州大学 | 一种用于快速初步筛选具有免疫调节功能益生菌的方法 |
-
2012
- 2012-12-12 FR FR1261916A patent/FR2999191B1/fr active Active
-
2013
- 2013-12-12 TW TW102145855A patent/TWI602921B/zh active
- 2013-12-12 CN CN201380064960.8A patent/CN105008924B9/zh active Active
- 2013-12-12 ES ES13820807.9T patent/ES2692660T3/es active Active
- 2013-12-12 DK DK13820807.9T patent/DK2932265T3/en active
- 2013-12-12 RU RU2015128101A patent/RU2642320C2/ru active
- 2013-12-12 EP EP13820807.9A patent/EP2932265B1/fr active Active
- 2013-12-12 US US14/649,763 patent/US20160000840A1/en not_active Abandoned
- 2013-12-12 SG SG11201504542PA patent/SG11201504542PA/en unknown
- 2013-12-12 JP JP2015547122A patent/JP6401180B2/ja active Active
- 2013-12-12 WO PCT/FR2013/053044 patent/WO2014091160A1/fr active Application Filing
- 2013-12-12 KR KR1020157015784A patent/KR102181606B1/ko active Active
- 2013-12-12 CA CA2893990A patent/CA2893990C/fr active Active
-
2015
- 2015-06-04 PH PH12015501273A patent/PH12015501273B1/en unknown
-
2018
- 2018-10-10 US US16/156,576 patent/US10736925B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2837835B2 (ja) * | 1996-05-15 | 1998-12-16 | オリンパス光学工業株式会社 | 射出成形機における金型要素自動交換方法 |
KR20080073771A (ko) * | 2005-11-29 | 2008-08-11 | 케민 인더스트리즈, 인코포레이티드 | 위장관 및 면역-관련 질환의 예방 및 치료를 위한 바실루스pb6의 용도 |
Non-Patent Citations (3)
Title |
---|
Raheja et al., American journal of Physiology-Gastrointestinal and Liver Physiology, Vol. 298, 2010, G395-G401. * |
S.Lin et al., Gastroenterology, Vol. 138, No. 2, 2010, pp. 649-658. * |
Singh et al., American Journal of Physiology Gastrointest Liver Physiology, 303, (2012.10.18.), pp. G1393-G1401.* * |
Also Published As
Publication number | Publication date |
---|---|
WO2014091160A1 (fr) | 2014-06-19 |
SG11201504542PA (en) | 2015-07-30 |
CN105008924B9 (zh) | 2017-04-19 |
PH12015501273A1 (en) | 2015-08-24 |
CN105008924A (zh) | 2015-10-28 |
EP2932265B1 (fr) | 2018-08-15 |
ES2692660T3 (es) | 2018-12-04 |
JP2016505254A (ja) | 2016-02-25 |
CA2893990A1 (fr) | 2014-06-19 |
FR2999191A1 (fr) | 2014-06-13 |
JP6401180B2 (ja) | 2018-10-03 |
CA2893990C (fr) | 2021-05-11 |
TW201437373A (zh) | 2014-10-01 |
US20160000840A1 (en) | 2016-01-07 |
PH12015501273B1 (en) | 2019-08-23 |
US20190038681A1 (en) | 2019-02-07 |
FR2999191B1 (fr) | 2016-02-05 |
TWI602921B (zh) | 2017-10-21 |
DK2932265T3 (en) | 2018-11-26 |
RU2642320C2 (ru) | 2018-01-24 |
RU2015128101A (ru) | 2017-01-19 |
EP2932265A1 (fr) | 2015-10-21 |
CN105008924B (zh) | 2017-03-08 |
KR102181606B1 (ko) | 2020-11-23 |
US10736925B2 (en) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10736925B2 (en) | Probiotics strains for treating and/or preventing diarrhea | |
EP2179028B1 (en) | A novel strain of bifidobacterium and active peptides against rotavirus infections | |
CN105106246A (zh) | 一种植物乳杆菌zs2058及其用途 | |
Matur et al. | The impact of probiotics on the gastrointestinal physiology | |
US11376289B2 (en) | Composition and uses thereof | |
US12128077B2 (en) | Strains, composition and method of use | |
US20220401499A1 (en) | New use of bifidobacterium lactis bl-99 in suppression of intestinal inflammation | |
CN117838737A (zh) | 一种短双歧杆菌207-1及其在调节脂代谢方向的应用 | |
Ren et al. | Lactobacillus paracasei influences the gut-microbiota-targeted metabolic modulation of the immune status of diarrheal mice | |
US20150284675A1 (en) | Streptococcus thermophilus strains for treating helicobacter pylori infection | |
US20220054558A1 (en) | Compositions comprising bacterial strains | |
US9272007B2 (en) | Strain of L. bulgaricus capable of inhibiting the adhesion of H. pylori strains to epithelial cells | |
WO2019129807A1 (en) | Serpin production | |
Chaudhari et al. | Bacillus Coagulans SKB LAB-19: a potential probiotic in humans and animal Healthcare | |
Wang et al. | Probiotic potential of Bacillus isolated from horses and its therapeutic effect against DSS-induced colitis in mice | |
WO2025131132A1 (zh) | 一种后生元及其在调节脂代谢方向的应用 | |
Pachenari | An investigation of the potential of selected strains of Bifidobacterium to colonise the gastrointestinal tract of mice | |
Mullangi | Development and evaluation of in vitro intestinal epithelial models to study ameliorative effects of probiotics on inflammation induced barrier dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20150612 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20181015 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200331 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20201027 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20201117 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20201117 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20231108 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20241105 Start annual number: 5 End annual number: 5 |